Return to homepagePandemic Pact

Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1R01AR080659-01A1

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2023
    2028

  • Known Financial Commitments (USD)

    $782,510

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    ASSOCIATE PHYSICIAN Jeffrey Sparks

  • Research Location

    United States of America

  • Lead Research Institution

    BRIGHAM AND WOMEN'S HOSPITAL

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Other

  • Occupations of Interest

    Unspecified

Abstract

PROJECT SUMMARY The 5 million Americans living with systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), are at increased risk of poor COVID-19 outcomes. SARO treatment with immunomodulators may lead to blunted and dysregulated immune responses to vaccination and infection. SARDs are characterized by a predisposition to autoantibody formation and fibrosis. These factors may place SARDs at risk for poor short-term outcomes (e.g., breakthrough infection, prolonged viral shedding) and post-acute sequelae of COVID-19 (PASC), characterized by prolonged COVID-19 symptoms (>/=28 days). PASC is of high clinical and